New Chemistry Analyzer Completes Ortho Clinical Diagnostics’ Catalogue of VITROS XT Solutions
|
By LabMedica International staff writers Posted on 09 Mar 2020 |

Image: The VITROS XT 3400 Chemistry System (Photo courtesy of Ortho Clinical Diagnostics)
Ortho Clinical Diagnostics (Raritan, NJ, USA) has announced the launch and availability of the VITROS XT 3400 Chemistry System, which completes the company’s catalogue of VITROS XT Solutions.
The new CE-marked VITROS XT 3400 Chemistry System, like the VITROS XT 7600 Integrated System, simultaneously performs two tests frequently ordered together on one VITROS XT MicroSlide, a multi-layered, postage-stamp sized slide which filters out lipids and proteins that can impinge the quality of results, and offers an up-to-40% higher throughput than current slides.
Double assay processing offers a 25% faster turnaround time on a common panel of assays, with an average processing time of 7.5 minutes compared to about 10 minutes for other industry options. Furthermore, the XT MicroSlide allows for the lowest sample volume at 2.7 microliters.
Reduction in external factors that could effect results ensures the accuracy of tests performed on VITROS XT Solutions. Thus, Ortho’s proprietary “dry” chemistry technology does not require water, which eliminates the risk that poor water quality could impact results. In addition, single-use tips and cuvettes eliminate the risk for both sample and reagent carryover.
“Because Every Test is a Life, we make patient care our passion at Ortho Clinical Diagnostics,” said Chris Smith, CEO of Ortho Clinical Diagnostics. “Driven by this, we work diligently to ensure the world’s labs are best equipped to partner with clinicians and medical teams to provide consistently fast, accurate results that help them confidently diagnose, monitor and treat their patients.”
Related Links:
Ortho Clinical Diagnostics
The new CE-marked VITROS XT 3400 Chemistry System, like the VITROS XT 7600 Integrated System, simultaneously performs two tests frequently ordered together on one VITROS XT MicroSlide, a multi-layered, postage-stamp sized slide which filters out lipids and proteins that can impinge the quality of results, and offers an up-to-40% higher throughput than current slides.
Double assay processing offers a 25% faster turnaround time on a common panel of assays, with an average processing time of 7.5 minutes compared to about 10 minutes for other industry options. Furthermore, the XT MicroSlide allows for the lowest sample volume at 2.7 microliters.
Reduction in external factors that could effect results ensures the accuracy of tests performed on VITROS XT Solutions. Thus, Ortho’s proprietary “dry” chemistry technology does not require water, which eliminates the risk that poor water quality could impact results. In addition, single-use tips and cuvettes eliminate the risk for both sample and reagent carryover.
“Because Every Test is a Life, we make patient care our passion at Ortho Clinical Diagnostics,” said Chris Smith, CEO of Ortho Clinical Diagnostics. “Driven by this, we work diligently to ensure the world’s labs are best equipped to partner with clinicians and medical teams to provide consistently fast, accurate results that help them confidently diagnose, monitor and treat their patients.”
Related Links:
Ortho Clinical Diagnostics
Latest Technology News
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Channels
Clinical Chemistry
view channel
Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
Breast cancer is the most commonly diagnosed cancer among women globally and remains a leading cause of cancer-related deaths in more than 100 countries. Current diagnostic pathways rely on mammography,... Read more
New Tool Tracks Biomarker Changes to Predict Myeloma Progression
Smoldering multiple myeloma (SMM) precedes multiple myeloma and poses a monitoring challenge because progression risk varies widely among patients. Static, one-time laboratory assessments can miss clinically... Read moreMolecular Diagnostics
view channel
Blood Biomarker Predicts Cognitive Outcomes After Cardiac Arrest
Long-term cognitive impairment is a frequent consequence of out-of-hospital cardiac arrest yet early prediction remains difficult. Clinicians commonly use blood-based markers to estimate brain injury risk... Read more
Liquid Biopsy Enables Faster Diagnosis of Childhood Cancer in Africa
Burkitt lymphoma is the most common childhood cancer in Africa and progresses rapidly, making fast, accurate diagnosis essential to survival. Although survival can exceed 90% when therapy starts quickly,... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read more
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read moreMicrobiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read more
New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
Invasive Candida infections are challenging for healthcare systems, with some strains spreading rapidly in hospitals and showing resistance to multiple antifungal drugs. Candida auris is associated with... Read moreIndustry
view channel
Co-Diagnostics Agreement Expands Commercial and Distribution Reach in South Asia
Co-Diagnostics (Co-Dx; Salt Lake City, UT, USA) has signed an agreement for CoSara Diagnostics Pvt. Ltd., its Indian joint venture with Ambalal Sarabhai Enterprises Limited (Ahmedabad, India), to extend... Read more








